June 2026
1. YIN P, Boyce R, Wang S, Sirrine M, et al
   Identification and characterization of novel chikungunya virus polymerase inhibitors.
   J Virol. 2026;100:e0030526.
   

   >> Share

   
   April 2026
2. CHEN L, Su H, Shang W, Nie T, et al
   SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.
   J Virol. 2026 Apr 27:e0222325. doi: 10.1128/jvi.02223.
   

   >> Share

   
   February 2026
3. WONG J, Moore T, Lewis D, Lieber CM, et al
   Impact of mutations affecting 4'-fluorouridine susceptibility on fitness and treatment outcomes for Venezuelan equine encephalitis virus.
   J Virol. 2026;100:e0154125.
   

   >> Share

   
   January 2026
4. YANG Q, Xue B, Qiu X, Yang K, et al
   Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
   J Virol. 2026;100:e0148725.
   

   >> Share

   
   October 2025
5. GOURIN C, Di Meo F, Delmon C, Alain S, et al
   Functional and structural insights into HCMV terminase accessory proteins pUL77 and pUL93.
   J Virol. 2025;99:e0117325.
   

   >> Share

   
   August 2025
6. MA Y, Ye C, Khalil AM, Mahmoud SH, et al
   A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.
   J Virol. 2025 Aug 7:e0082125. doi: 10.1128/jvi.00821.
   

   >> Share

   
   April 2025
7. HUANG Y, Liang G, Wang T, Ma Y, et al
   Research strategies of the N-peptide fusion inhibitor: a promising direction for discovering novel antivirals.
   J Virol. 2025 Apr 10:e0228924. doi: 10.1128/jvi.02289.
   

   >> Share

   
   March 2025
8. CHATTERJEE D, Niu L, Medjahed H, Ding S, et al
   A gp41 HR2 residue modulates the susceptibility of HIV-1 envelope glycoproteins to small molecule inhibitors targeting gp120.
   J Virol. 2025 Mar 27:e0226724. doi: 10.1128/jvi.02267.
   

   >> Share

   
   January 2025
9. FEDORCHENKO SV, Klimenko Z, Martynovich T, Solianyk I, et al
   Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.
   J Virol. 2025 Jan 22:e0184324. doi: 10.1128/jvi.01843.
   

   >> Share

   
   
10. COHEN P, Lambson BE, Mkhize NN, Moodley C, et al
    Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.
    J Virol. 2025 Jan 16:e0173024. doi: 10.1128/jvi.01730.
    

    >> Share

    
    
11. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.
    J Virol. 2025 Jan 10:e0123024. doi: 10.1128/jvi.01230.
    

    >> Share

    
    June 2024
12. LI S, Wei B, Xu L, Cong C, et al
    In vivo efficacy of phage cocktails against carbapenem resistance Acinetobacter baumannii in the rat pneumonia model.
    J Virol. 2024 Jun 12:e0046724. doi: 10.1128/jvi.00467.
    

    >> Share

    
    May 2024
13. DEKKER JG, Klaver B, Berkhout B, Das AT, et al
    Reverse transcription of HIV-1 2-LTR circle transcripts does frequently cause 3'-polypurine tract mutations implicated in dolutegravir resistance.
    J Virol. 2024 May 24:e0033524. doi: 10.1128/jvi.00335.
    

    >> Share

    
    February 2024
14. HAN P, Lin W, Fan H, Tong Y, et al
    Characterization of phage evolution and phage resistance in drug-resistant Stenotrophomonas maltophilia.
    J Virol. 2024;98:e0124923.
    

    >> Share

    
    January 2024
15. TAN X, Chen K, Jiang Z, Liu Z, et al
    Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions.
    J Virol. 2024;98:e0135923.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share